This is a multicenter, open-label, single-arm, phase 4, estimation study in subjects with plaque psoriasis(PsO) who have failed apremilast. The study will consist of a screening period of up to 45 days, a 24-week treatment period with study visits every 4-weeks, and a 30-day follow-up period for safety. Etanercept dosing will follow the recommended label dosing for subjects with plaque psoriasis.